What Happened?
Shares of medical device company DexCom (NASDAQ: DXCM) jumped 2.6% in the morning session after the company announced it would present new product features and positive clinical data at the European Association for the Study of Diabetes (EASD) 2025 conference.
The medical device maker planned to unveil its new "Smart Basal" module, an integrated system designed to make basal insulin management easier for users, currently under review by the FDA and for a CE mark.
Additionally, Dexcom planned to present new data reinforcing that its continuous glucose monitor (CGM) use reduced acute diabetes events and neonatal complications linked to gestational diabetes more effectively than traditional fingersticks.
After the initial pop the shares cooled down to $76.47, up 0.3% from previous close.
Is now the time to buy DexCom? Access our full analysis report here, it’s free.
What Is The Market Telling Us
DexCom’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock dropped 3.2% on the news that markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Stocks rose in the morning session after an unexpected drop in the Producer Price Index (PPI) for August signaled easing inflation and raised expectations for a potential Federal Reserve interest rate cut. The U.S. Bureau of Labor Statistics reported that the PPI, which measures wholesale prices, edged down 0.1% the previous month, contrary to analyst expectations for a 0.3% rise. This data gives the Federal Reserve more flexibility to consider lowering interest rates to stimulate the economy.
DexCom is down 2.6% since the beginning of the year, and at $76.47 per share, it is trading 15.7% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at an investment worth $768.60.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
